IFM Investors Pty Ltd Increases Stake in Pfizer Inc. $PFE

IFM Investors Pty Ltd raised its position in Pfizer Inc. (NYSE:PFE) by 4.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 1,229,480 shares of the biopharmaceutical company’s stock after acquiring an additional 54,721 shares during the period. IFM Investors Pty Ltd’s holdings in Pfizer were worth $34,524,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Horizon Financial Services LLC raised its holdings in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. purchased a new stake in Pfizer in the 4th quarter valued at approximately $26,000. YANKCOM Partnership acquired a new position in Pfizer during the 4th quarter worth approximately $28,000. HFM Investment Advisors LLC increased its position in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the period. Finally, Abound Financial LLC purchased a new position in shares of Pfizer during the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.08 on Wednesday. The firm has a market capitalization of $137.23 billion, a price-to-earnings ratio of 18.38 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The business’s 50 day simple moving average is $25.81 and its 200-day simple moving average is $26.27. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. Pfizer’s payout ratio is currently 131.30%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on PFE shares. HSBC raised their price target on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a report on Tuesday, June 23rd. Wolfe Research reissued an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. Finally, Citigroup boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.82.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s GLP-1 drug Ecnoglutide cleared a preliminary review for possible inclusion in China’s basic medical insurance drug catalogue, a potentially meaningful commercialization step for its obesity/diabetes pipeline. Article Title
• Positive Sentiment: Investor commentary continues to frame Pfizer as a value and income stock, citing its high dividend yield and low valuation metrics, which may be attracting bargain hunters. Article Title
• Positive Sentiment: Pfizer also signed a SuperHuman platform license agreement with Distributed Bio, suggesting continued dealmaking to strengthen its drug-development pipeline. Article Title
• Neutral Sentiment: Multiple market recaps said Pfizer traded lower while the market improved, but the stock still outperformed some competitors, indicating the move may have been more about sector sentiment than company-specific news. Article Title
• Neutral Sentiment: Pfizer completed a real-world COVID-19 vaccine study and investors are awaiting data release, which could matter for sentiment but is not yet a confirmed catalyst. Article Title
• Negative Sentiment: Bearish commentary continues to focus on fading COVID franchise sales, with one article noting sharp declines in Comirnaty and Paxlovid revenue, reinforcing concerns about Pfizer’s near-term growth outlook. Article Title

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.